drugset

drugset / Trial / NCT07054684

Study of BHV-1400 in IgA Nephropathy

NCT07054684 ↗

Phase 1 Recruiting 20 enrolled Biohaven Therapeutics Ltd.

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN).

Timeline

Start: 2025-07-30
Primary completion: 2027-07
Completion: 2027-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BHV-1400	Unknown	—	Subcutaneous

Indications